Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
No clinically meaningful differences in safety results between the nirsevimab and placebo groups were seen.
- No clinically meaningful differences in safety results between the nirsevimab and placebo groups were seen.
- \xe2\x80\x9cIn fact, most hospitalizations occur in otherwise healthy infants born at term.
- It\xe2\x80\x99s clear all infants need protection from RSV, and we hope nirsevimab becomes an important addition to routine immunization schedules.\xe2\x80\x9d\n\xe2\x80\x9cThese ground-breaking results mark a major scientific advancement in our effort to provide protection against respiratory syncytial virus for all infants.
- Nearly all children will contract the virus before age two, leading to nearly 30 million acute lower respiratory tract infections globally each year,\xe2\x80\x9d said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.